Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking.
The objective of this study was to study the significance of tumor necrosis documented at the time of interval surgical debulking after neoadjuvant chemotherapy. Retrospective chart reviews were carried out from 1997 to 2005 to identify ovarian cancer patients treated with neoadjuvant chemotherapy. Patients' demographics together with disease characteristics, treatment-related variables, and outcomes were recorded. Cox proportional hazard models were built to model time to progression using predictor variables such as age, cancer stage, tumor grade, residual disease, percentage change in CA125 level from baseline, and degree of necrosis in resected tumor specimens. One hundred one patients were included in the study. Optimal debulking was achieved in 74% of the patients. Cox regressions revealed three significant predictive variables of time to first progression: younger age (hazard ratio [HR] = 0.95, 95% CI 0.92-0.98, P= 0.004), residual disease (P= 0.048), and the absence/minimal tumor necrosis after three cycles of neoadjuvant chemotherapy (HR = 1.97, 95% CI 1.01-3.87, P= 0.048). The estimated median survival was 50.66 months (95% CI 46.12-55.20). The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease.
Le
T
T
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa General Hospital, 501 Smyth Road, Ottawa, Ontario, Canada. tle@ottawahospital.on.ca
Shahriari
P
P
Hopkins
L
L
Faught
W
W
Fung Kee Fung
M
M
D018262:Adenocarcinoma, Clear Cell / Q000175:diagnosis; D002288:Adenocarcinoma, Mucinous / Q000175:diagnosis; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D019540:Area Under Curve; D018394:CA-125 Antigen / Q000032:analysis; D016190:Carboplatin / Q000627:therapeutic use; D002277:Carcinoma / Q000175:diagnosis; D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000175:diagnosis; D005260:Female; D006801:Humans; D009336:Necrosis; D020360:Neoadjuvant Therapy; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D010052:Ovariectomy / Q000706:statistics & numerical data; D017239:Paclitaxel / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D024162:Second-Look Surgery / Q000379:methods; D015996:Survival Rate
D018394:CA-125 Antigen; D016190:Carboplatin; D017239:Paclitaxel